Capecitabine for Breast Cancer

This trial aims to determine if the drug capecitabine can benefit individuals with Stage I-III HR+/HER2-negative breast cancer who still have molecular residual disease despite standard treatment. Participants will take capecitabine pills three times daily for up to a year to assess its effectiveness in preventing cancer recurrence. The trial seeks participants who have completed standard breast cancer treatments but still have detectable cancer cells. This study focuses on improving outcomes for those with molecular residual disease after initial treatment. As a Phase 2 trial, the research measures the treatment's effectiveness in an initial, smaller group of participants.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Research has shown that capecitabine is generally well-tolerated by many patients, including those with extensive prior cancer treatments. Most do not experience severe side effects. Common mild effects may include fatigue or slight nausea, while serious problems are rare.

One study found that a lower dose of capecitabine reduced side effect risks without compromising effectiveness. Another study reported minimal issues like low blood cell count or hair loss, which are common with many cancer treatments.

Capecitabine is unique because it's a chemotherapy pill that can be taken orally, unlike many traditional breast cancer treatments that require intravenous administration. This means it's more convenient for patients, allowing them to take their medication at home without frequent hospital visits. Additionally, it works by interfering with the DNA of cancer cells, blocking their growth, which is a targeted approach that can potentially reduce side effects compared to more generalized chemotherapy options. Researchers are excited about Capecitabine because it offers a promising alternative that could improve the quality of life for patients while effectively treating breast cancer.

Studies have shown that capecitabine can improve outcomes for breast cancer patients. For those with HER2-negative breast cancer, taking capecitabine after surgery helps patients remain cancer-free for longer. In one study, three years after treatment, 82.8% of patients who took capecitabine were alive and showed no signs of cancer, compared to 73.9% of those who did not take the drug. Other research has also demonstrated a significant decrease in the risk of cancer returning or spreading. These findings suggest that capecitabine could help patients with certain types of breast cancer live longer without cancer recurrence.³⁶⁷⁸⁹